FDA refuses to file Merck application for combo of ezetimibe and atorvastatin 1

The FDA has refused to accept Merck’s application for a  combination  drug consisting of ezetimibe and atorvastatin. Here is the statement from Merck, buried on page 46 of Merck’s quarterly report:

The Company submitted for filing an NDA with the FDA for MK-0653C, ezetimibe combined with atorvastatin, which is an investigational medication for the treatment of dyslipidemia being developed by the MSP Partnership, and the FDA recently refused to file the application. The FDA has identified additional manufacturing and stability data that are needed and the Company is assessing the FDA’s response in order to determine a new timetable for filing.

One comment

  1. Pingback: Merck’s Combination Of Ezetimibe And Atorvastatin Combo Back On NDA Path « CardioBrief

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s